サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1139891

心的外傷後ストレス障害治療市場：治療タイプ別、年齢層別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Post-Traumatic Stress Disorder Treatment Market By Treatment Type, By Age Group, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 245 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
心的外傷後ストレス障害治療市場：治療タイプ別、年齢層別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年
出版日: 2022年06月01日
発行: Allied Market Research
ページ情報: 英文 245 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心的外傷後ストレス障害治療の世界市場は、2021年には159億7664万米ドル、2031年には260億6075万米ドルに達すると予測され、2022年から2031年までCAGR4.9%で成長すると予測しています。

心的外傷後ストレス障害は、精神衛生に関連する深刻な状態です。生命を脅かす出来事、繰り返される不安、性的虐待、トラウマとなる出来事の内面的な記憶などが原因となって起こります。この障害の症状には、フラッシュバック、悪夢、気分の変動、身体活動の変化、事件に関する制御不能な思考が含まれ、患者のストレス状態を引き起こす可能性があります。心的外傷後ストレス障害（PTSD）は、日常生活に支障をきたすような不穏な症状を特徴とする精神障害です。PTSDの症状は、トラウマとなる出来事の後すぐに始まることもあれば、出来事の後何年も経ってから現れることもあります。トラウマを思い出させる侵入記憶や追体験、トラウマを思い出させるもの回避、トラウマの結果生じた思考や気分のネガティブな変化、日常的な出来事に対する感情反応の変化などがあります。

心的外傷後ストレス障害治療の世界市場は、世界の事故や事件の増加による心的外傷後ストレス障害の有病率の上昇が主な要因となっています。また、臨床試験の増加や老年人口の増加が、今後の市場成長を牽引します。しかし、薬物治療に伴う副作用が市場の妨げになることが予想されます。さらに、心的外傷後ストレス障害に対する抗うつ薬の研究開発活動の増加、心的外傷後ストレス障害治療管理のための政府のイニシアティブの上昇、新興国における医療費の増加は、市場の成長を押し上げる主な要因となっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 心的外傷後ストレス障害治療薬市場：治療薬タイプ別

  • 概要
    • 市場規模および予測
  • 薬物
    • 主な市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場分析：国別
  • 精神療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 心的外傷後ストレス障害治療市場：年齢層別

  • 概要
    • 市場規模および予測
  • ペディアルティック
    • 主な市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場分析：国別
  • 老年用医薬品
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 成人病
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 心的外傷後ストレス障害治療薬市場：エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院
    • 主な市場動向、成長要因、機会
    • 市場規模・予測： 地域別
    • 市場分析：国別
  • 外来診療所
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 精神科医療センター
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第7章 心的外傷後ストレス障害治療市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測：治療タイプ別
    • 北米市場規模・予測：年齢層別
    • 北米市場規模・予測：エンドユーザー別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測：治療タイプ別
    • 欧州市場規模・予測：年齢層別
    • 欧州市場規模・予測：エンドユーザー別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：治療タイプ別
    • アジア太平洋地域の市場規模・予測：年齢層別
    • アジア太平洋地域の市場規模・予測：エンドユーザー別
    • アジア太平洋地域の市場規模・予測：国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：治療タイプ別
    • LAMEAの市場規模・予測：年齢層別
    • LAMEAの市場規模・予測：エンドユーザー別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Acadia Healthcare
  • Behavioral Health Network, Inc
  • Caretech Holdings PLC
  • GlaxoSmithKline Plc
  • Pfizer, Inc
  • Viatris, Inc
  • Strategic Behavioral Health
  • North Range Behavioral Health
  • Pyramid Healthcare
  • Eily Lilly and Company
図表

LIST OF TABLES

  • TABLE 1. GLOBAL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 2. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR DRUGS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR PYSCHOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR PYSCHOTHERAPY BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 7. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR PEDIARTIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR PEDIARTIC BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR GERIATRIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR GERIATRIC BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR ADULT BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. GLOBAL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 14. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR HOSPITALS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR OUTPAITENT CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR OUTPAITENT CLINICS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR MENTAL HEALTH CENTER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR MENTAL HEALTH CENTER BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 22. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. NORTH AMERICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 24. NORTH AMERICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 27. U.S. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 28. U.S. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 29. U.S. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 30. CANADA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 31. CANADA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 32. CANADA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 33. MEXICO POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 34. MEXICO POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 35. MEXICO POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 36. EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 37. EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 38. EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 39. EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 40. GERMANY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 41. GERMANY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 42. GERMANY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 43. FRANCE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 44. FRANCE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 45. FRANCE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 46. U.K. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 47. U.K. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 48. U.K. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 49. ITALY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 50. ITALY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 51. ITALY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 52. SPAIN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 53. SPAIN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 54. SPAIN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 55. REST OF EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 56. REST OF EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 57. REST OF EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 58. ASIA-PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 59. ASIA-PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 60. ASIA-PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 61. ASIA-PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 62. JAPAN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 63. JAPAN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 64. JAPAN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. CHINA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 66. CHINA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 67. CHINA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 68. AUSTRALIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 69. AUSTRALIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 70. AUSTRALIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 71. INDIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 72. INDIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 73. INDIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 74. SOUTH KOREA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 75. SOUTH KOREA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 76. SOUTH KOREA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 77. REST OF ASIA PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 78. REST OF ASIA PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 80. LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 81. LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 82. LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 84. BRAZIL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 85. BRAZIL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 86. BRAZIL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 87. SAUDI ARABIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 88. SAUDI ARABIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 89. SAUDI ARABIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 90. SOUTH AFRICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 91. SOUTH AFRICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 92. SOUTH AFRICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 93. REST OF LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 94. REST OF LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 95. REST OF LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 96.ACADIA HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 97.ACADIA HEALTHCARE: OPERATING SEGMENTS
  • TABLE 98.ACADIA HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 99.ACADIA HEALTHCARE: NET SALES,
  • TABLE 100.ACADIA HEALTHCARE: KEY STRATERGIES
  • TABLE 101.BEHAVIORAL HEALTH NETWORK, INC: COMPANY SNAPSHOT
  • TABLE 102.BEHAVIORAL HEALTH NETWORK, INC: OPERATING SEGMENTS
  • TABLE 103.BEHAVIORAL HEALTH NETWORK, INC: PRODUCT PORTFOLIO
  • TABLE 104.BEHAVIORAL HEALTH NETWORK, INC: NET SALES,
  • TABLE 105.BEHAVIORAL HEALTH NETWORK, INC: KEY STRATERGIES
  • TABLE 106.CARETECH HOLDINGS PLC: COMPANY SNAPSHOT
  • TABLE 107.CARETECH HOLDINGS PLC: OPERATING SEGMENTS
  • TABLE 108.CARETECH HOLDINGS PLC: PRODUCT PORTFOLIO
  • TABLE 109.CARETECH HOLDINGS PLC: NET SALES,
  • TABLE 110.CARETECH HOLDINGS PLC: KEY STRATERGIES
  • TABLE 111.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 112.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 113.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 114.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 115.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 116.PFIZER, INC: COMPANY SNAPSHOT
  • TABLE 117.PFIZER, INC: OPERATING SEGMENTS
  • TABLE 118.PFIZER, INC: PRODUCT PORTFOLIO
  • TABLE 119.PFIZER, INC: NET SALES,
  • TABLE 120.PFIZER, INC: KEY STRATERGIES
  • TABLE 121.VIATRIS, INC: COMPANY SNAPSHOT
  • TABLE 122.VIATRIS, INC: OPERATING SEGMENTS
  • TABLE 123.VIATRIS, INC: PRODUCT PORTFOLIO
  • TABLE 124.VIATRIS, INC: NET SALES,
  • TABLE 125.VIATRIS, INC: KEY STRATERGIES
  • TABLE 126.STRATEGIC BEHAVIORAL HEALTH: COMPANY SNAPSHOT
  • TABLE 127.STRATEGIC BEHAVIORAL HEALTH: OPERATING SEGMENTS
  • TABLE 128.STRATEGIC BEHAVIORAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 129.STRATEGIC BEHAVIORAL HEALTH: NET SALES,
  • TABLE 130.STRATEGIC BEHAVIORAL HEALTH: KEY STRATERGIES
  • TABLE 131.NORTH RANGE BEHAVIORAL HEALTH: COMPANY SNAPSHOT
  • TABLE 132.NORTH RANGE BEHAVIORAL HEALTH: OPERATING SEGMENTS
  • TABLE 133.NORTH RANGE BEHAVIORAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 134.NORTH RANGE BEHAVIORAL HEALTH: NET SALES,
  • TABLE 135.NORTH RANGE BEHAVIORAL HEALTH: KEY STRATERGIES
  • TABLE 136.PYRAMID HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 137.PYRAMID HEALTHCARE: OPERATING SEGMENTS
  • TABLE 138.PYRAMID HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 139.PYRAMID HEALTHCARE: NET SALES,
  • TABLE 140.PYRAMID HEALTHCARE: KEY STRATERGIES
  • TABLE 141.EILY LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 142.EILY LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 143.EILY LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 144.EILY LILLY AND COMPANY: NET SALES,
  • TABLE 145.EILY LILLY AND COMPANY: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET SEGMENTATION
  • FIGURE 2.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 3.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,BY TREATMENT TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DRUGS POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PYSCHOTHERAPY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,BY AGE GROUP,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PEDIARTIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GERIATRIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ADULT POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,BY END USER,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITALS POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OUTPAITENT CLINICS POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF MENTAL HEALTH CENTER POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET BY REGION,2021
  • FIGURE 25.U.S. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.U.K. POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA PACIFIC POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SAUDI ARABIA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH AFRICA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.ACADIA HEALTHCARE.: NET SALES ,($MILLION)
  • FIGURE 51.BEHAVIORAL HEALTH NETWORK, INC.: NET SALES ,($MILLION)
  • FIGURE 52.CARETECH HOLDINGS PLC.: NET SALES ,($MILLION)
  • FIGURE 53.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 54.PFIZER, INC.: NET SALES ,($MILLION)
  • FIGURE 55.VIATRIS, INC.: NET SALES ,($MILLION)
  • FIGURE 56.STRATEGIC BEHAVIORAL HEALTH.: NET SALES ,($MILLION)
  • FIGURE 57.NORTH RANGE BEHAVIORAL HEALTH.: NET SALES ,($MILLION)
  • FIGURE 58.PYRAMID HEALTHCARE.: NET SALES ,($MILLION)
  • FIGURE 59.EILY LILLY AND COMPANY.: NET SALES ,($MILLION)
目次
Product Code: A12600

The global post-traumatic stress disorder treatment market was valued at $15,976.64 million in 2021 and is projected to reach $26,060.75 million by 2031, registering a CAGR of 4.9% from 2022 to 2031. Post-traumatic stress disorder is a serious condition related to mental health. It is caused due to life-threatening events, recurrent anxiety, sex abuse & internal reminder of traumatic events. The symptoms of the disorder include flashbacks, nightmares, swings of mood, changes in physical activities & uncontrollable thoughts about the incident that may cause a stressed condition for the patient. Post-Traumatic Stress Disorder (PTSD) is a mental disorder characterized by disturbing symptoms that interfere with daily functioning. PTSD symptoms may start very quickly following a traumatic event, or they might not appear for years after the event including intrusive memories or reliving of the experience, avoidance of anything that reminds the person of the trauma, negative changes in thinking or mood that are a result of the trauma and which interfere with daily functioning, and changes in the person's emotional reactions to everyday events.

The global post-traumatic stress disorder treatment market is majorly driven by an increase in the prevalence of post-traumatic stress disorder due to the increase in the number of accidents or incidents across the globe. In addition, an increase in clinical trials and a rise in the geriatric population drives the growth of the market in upcoming years. However, side effects associated with drug treatment are expected to hamper the market. Moreover, the increase in research & development activities for antidepressant drugs against post-traumatic stress disorder, rise in government initiatives for post-traumatic stress disorder treatment management, and increase in healthcare expenditure in developing countries are the key factor that boosts the growth of the market.

The post-traumatic stress disorder treatment market is segmented on the basis of treatment type, age group, end-user, and region. On the basis of treatment type, the market is divided into drugs and psychotherapy. By drugs, the market is classified into antidepressants, antipsychotics, beta-blockers, benzodiazepines, and others. Psychotherapy, the market is divided into cognitive behavior therapy, psychodynamic therapy, and others. On the basis of age, the market is divided into geriatric, pediatric, and adults. By end-user, the market is classified into hospitals, outpatients' clinics, mental health centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

.The key players operating in the global post-traumatic stress disorder treatment market are Acadia Healthcare, Behavioral Health Network, Inc., CareTech Holdings Plc, GlaxoSmithKline Plc, Pfizer, Inc, Viatris, Inc, Strategic Behavioral Health, Ascension Seton, North Range Behavioral Health, Pyramid Healthcare and Eily Lilly and Company.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the post-traumatic stress disorder treatment market analysis from 2021 to 2031 to identify the prevailing post-traumatic stress disorder treatment market opportunities.
  • The Market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the post-traumatic disorder treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global post-traumatic stress disorder treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Treatment Type

  • Drugs
  • Pyschotherapy

By Age Group

  • Pediartic
  • Geriatric
  • Adult

By End User

  • Mental Health Center
  • Others
  • Hospitals
  • Outpaitent Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Spain
    • Rest of Europe
    • Germany
    • France
    • U.K.
    • Italy
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Acadia Healthcare
    • Behavioral Health Network, Inc
    • Caretech Holdings PLC
    • GlaxoSmithKline Plc
    • Pfizer, Inc
    • Viatris, Inc
    • Strategic Behavioral Health
    • North Range Behavioral Health
    • Pyramid Healthcare
    • Eily Lilly and Company

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Drugs
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Pyschotherapy
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY AGE GROUP

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Pediartic
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Geriatric
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Adult
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Outpaitent Clinics
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Mental Health Center
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Others
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country

CHAPTER 7: POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Treatment Type
    • 7.2.3 North America Market size and forecast, by Age Group
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Treatment Type
      • 7.2.5.1.2 Market size and forecast, by Age Group
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Treatment Type
      • 7.2.5.2.2 Market size and forecast, by Age Group
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Treatment Type
      • 7.2.5.3.2 Market size and forecast, by Age Group
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Treatment Type
    • 7.3.3 Europe Market size and forecast, by Age Group
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Treatment Type
      • 7.3.5.1.2 Market size and forecast, by Age Group
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Treatment Type
      • 7.3.5.2.2 Market size and forecast, by Age Group
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 U.K.
      • 7.3.5.3.1 Market size and forecast, by Treatment Type
      • 7.3.5.3.2 Market size and forecast, by Age Group
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Treatment Type
      • 7.3.5.4.2 Market size and forecast, by Age Group
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Treatment Type
      • 7.3.5.5.2 Market size and forecast, by Age Group
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Treatment Type
      • 7.3.5.6.2 Market size and forecast, by Age Group
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Treatment Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Age Group
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Treatment Type
      • 7.4.5.1.2 Market size and forecast, by Age Group
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Treatment Type
      • 7.4.5.2.2 Market size and forecast, by Age Group
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Treatment Type
      • 7.4.5.3.2 Market size and forecast, by Age Group
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Treatment Type
      • 7.4.5.4.2 Market size and forecast, by Age Group
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Treatment Type
      • 7.4.5.5.2 Market size and forecast, by Age Group
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest Of Asia Pacific
      • 7.4.5.6.1 Market size and forecast, by Treatment Type
      • 7.4.5.6.2 Market size and forecast, by Age Group
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Treatment Type
    • 7.5.3 LAMEA Market size and forecast, by Age Group
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Treatment Type
      • 7.5.5.1.2 Market size and forecast, by Age Group
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Treatment Type
      • 7.5.5.2.2 Market size and forecast, by Age Group
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Treatment Type
      • 7.5.5.3.2 Market size and forecast, by Age Group
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Treatment Type
      • 7.5.5.4.2 Market size and forecast, by Age Group
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Acadia Healthcare
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Behavioral Health Network, Inc
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Caretech Holdings PLC
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 GlaxoSmithKline Plc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Pfizer, Inc
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Viatris, Inc
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Strategic Behavioral Health
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 North Range Behavioral Health
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Pyramid Healthcare
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Eily Lilly and Company
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments